Structure Therapeutics Launches Phase 1 Study of ACCG-2671 for Obesity
Structure Therapeutics Inc. has initiated a Phase 1 clinical study of its lead oral small molecule, ACCG-2671, aimed at treating obesity. The announcement, made on December 17, 2025, marks a…